https://doi.org/10.55788/1e3ee42f
Current guidelines of the European Society of Cardiology (ESC) recommend a natriuresis-guided diuretic use in acute heart failure (HF) following a position statement from the HFA [1,2]. To test whether a standardised diuretic protocol is superior to standard-of-care, Dr Jeroen Dauw (AZ Sint-Lucas, Belgium) and colleagues performed the prospective, multicentre, open-label, non-randomised, pragmatic ENACT-HF trial [3]. The study included 29 centres in 18 countries worldwide. In each centre, standard-of-care was compared with a standardised diuretic protocol in 2 sequential phases of recruitment: standard-of-care was used in phase 1, and the standardised protocol was followed in phase 2.
All 401 study participants had been admitted with acute HF and had at least 1 sign of volume overload. The primary endpoint was natriuresis after 1 day. Secondary endpoints included natriuresis and diuresis after 2 days, weight loss after 2 days, change in a congestion score, and duration of hospitalisation.
Following the standardised protocol led to an increase in natriuresis of 64% after 1 day (natriuresis after 1 day was 174 mmol in the standard-of-care group compared with 282 mmol in the protocol group; 95% CI 1.37–1.95; P<0.001; see Figure). A predefined subgroup analysis revealed that these results remained true independent of age, sex, kidney function, and left ventricular ejection fraction. “Those with a lower glomerular filtration rate had an even higher benefit,” Dr Dauw said.
Figure: A standardised diuretic protocol led to a 64% increase in natriuresis after 1 day in the ENACT-HF trial [3]
The effect of the protocol was also seen in both natriuresis and diuresis on day 2. They were significantly higher in the group following the diuretic protocol (P<0.001 for both comparisons). No differences were seen in weight loss and congestion score after 2 days but, according to Dr Dauw, weight loss is possibly less reliable in a pragmatic design. “We had a high congestion score already at the beginning of the trial, it might therefore take more time for these patients to see a difference.” Patients following the standardised protocol had a 1-day shorter duration of hospitalisation. There were no differences in the safety endpoints between the standard-of-care and the diuretic protocol.
- Mullens W, et al. Eur J Heart Fail 2019;21:137–55.
- Metra M, et al. Eur J Heart Fail. 2023;Apr 26. Doi:10.1002/ejhf.2874.
- Dauw J. Efficacy of a standardised diuretic protocol in acute heart failure. Session Late breaking clinical trials: acute heart failure and patients monitoring, Heart Failure 2023, 20–23 May, Prague, Czechia.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Low concentrations of VEGF-C: a negative prognostic factor Next Article
HF patients with metabolic dysfunction at high risk to develop depressive symptoms »
« Low concentrations of VEGF-C: a negative prognostic factor Next Article
HF patients with metabolic dysfunction at high risk to develop depressive symptoms »
Table of Contents: HFA 2023
Featured articles
Chronic Heart Failure — What You Need to Know
Sacubitril/valsartan reduces natriuretic peptides in HF patients with ejection fraction >40%
Clinically relevant reduction in HF hospitalisation due to haemodynamic monitoring
TRACER-HF: Trientine reduced biomarkers up to 8 weeks
Dapagliflozin improves LAVI, LV mass, and concentration of natriuretic peptides after 6 months
NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
Novel Therapeutics in Cardiomyopathy
Patisiran benefits maintained over 18 months in patients with transthyretin amyloidosis
Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy
What is New in Acute Heart Failure?
Standardised diuretic protocol significantly increases natriuresis in acute HF
Low concentrations of VEGF-C: a negative prognostic factor
Prevention and Comorbid Conditions of Heart Failure
VOICE-COVID-II : Alexa successful in SARS-CoV-2 symptoms screening
HF patients with metabolic dysfunction at high risk to develop depressive symptoms
Best of the Posters
Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients
Protein-bound uremic toxins predict HF events and death in patients with CKD
Related Articles
February 18, 2021
Omecamtiv mecarbil improves outcomes in HFrEF-patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com